Cancer care is undergoing a profound transformation. Moving beyond the traditional focus on treating disease after it appears, modern medicine is embracing a proactive model that seeks to predict risk, prevent illness, personalize care, and actively engage patients in their own health journey. This revolutionary approach, known as the 4Ps of Personalized Medicine, is reshaping the future of healthcare.

Drawing on advances in genomics, data analytics, and interdisciplinary collaboration, [Book Title] explores how physicians, scientists, and patients are working together to create more precise and effective strategies for cancer prevention, diagnosis, and treatment. By integrating genetic profiles, biomarkers, lifestyle factors, and patient participation, the 4P model offers a powerful alternative to the traditional one-size-fits-all approach.

Showcasing the pioneering work of City of Hope, one of America's leading cancer centers, this volume features expert-authored chapters on major cancer types and the innovative applications of Predictive, Preventive, Personalized, and Participatory medicine in clinical practice. Contributors share cutting-edge insights into how personalized cancer care is transforming outcomes and improving quality of life.

Accessible yet authoritative, this book is an essential resource for healthcare professionals, researchers, students, and informed readers seeking to understand the next generation of cancer medicine and the promise of a more individualized future in healthcare.

Ravi Salgia, MD, PhD, is Chair of Medical Oncology & Therapeutics Research at City of Hope National Medical Center, in Duarte, California. Dr. Salgia also holds the Arthur and Rosalie Kaplan Chair in Medical Oncology. Previously, Dr. Salgia was Professor of Medicine, Pathology and Dermatology, and the Director of the Thoracic Oncology Program, and Aerodigestive Tract Program Translational Research at the University of Chicago. His research interests focus on novel therapeutics against lung cancer. Dr. Salgia has been honored with numerous awards, including being named one of the Top Doctors in America and awarded the Sun Pharma Distinguished Scientist Award (Clinical Sciences). Prior to his tenure at University of Chicago School of Medicine, Dr. Salgia was faculty at the Dana-Farber Cancer Institute and Harvard Medical School. He earned his undergraduate summa cum laude in mathematics, biology, and chemistry, and then his MD and PhD degrees from Loyola University in Chicago, IL, where he also completed fellowships in neurochemistry and physiology. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins University School of Medicine in Baltimore, MD, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston, MA, during which time he also served as a clinical fellow at Harvard Medical School in Boston. Dr. Salgia maintains a strong interest in chaos theory and fractals and their application to cancer, especially lung cancer.

Prakash Kulkarni, Ph.D., is Research Professor and Director of Translational Research in the Department of Medical Oncology and has a courtesy appointment in the Department of Systems Biology at the City of Hope National Medical Centre in Duarte, California. After receiving his PhD in biochemistry from India, he did postdoctoral training in biochemistry at the Indian Institute of Science and in cell biology at the New York University School of Medicine. He was an Assistant Professor at Johns Hopkins University School of Medicine where he was named the Irene and Bernard L. Schwartz Scholar of the Patrick Walsh Fund. He then moved to the W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, as a Research Associate Professor. Prior to joining Johns Hopkins, Prof. Kulkarni held Staff Scientist positions in the Division of Chemistry & Chemical Engineering, the Division of Biology at Caltech, and in the Department of Genetics at Yale University School of Medicine. His research interests are interdisciplinary and are focused on understanding at a system level how conformational dynamics of intrinsically disordered proteins and noise contribute to phenotypic switching, especially in cancer and evolution. Prof. Kulkarni was a Visiting Professor in the Department of Mathematics, and the Department of Bioengineering at the Indian Institute of Science and is currently a Visiting Professor in the Division of Biology and Biological Engineering at Caltech. He is a Fellow of the Royal Society of Biology, UK, and inducted Member, Sigma Xi, The Scientific Research Honor Society.